| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC23163 | CCT129202 Featured | CCT129202 is a potent, selective, ATP-competitive pan-Aurora kinase inhibitor with IC50 of 42, 198 and 227 nM for Aurora A, Aurora B and Aurora C, respectively. |
|
| DC10005 | CCT196969 Featured | CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity. |
|
| DC23828 | CCT241161 | CCT241161 is a potent pan-RAF inhibitor with IC50 of 30, 15 and 6 nM for BRAF, V600E-BRAF and C-RAF, also potently inhibits SRC and LCK (IC50=10 and 3 nM, respectively).. |
|
| DC9399 | CCT241533 (hydrochloride) | CCT241533 Hcl is a potent serine/threonine checkpoint kinase (Chk2) inhibitor with IC50 of 3 nM; shows minimal cross-reactivity against a panel of kinases at 1 uM. |
|
| DC10911 | CCT241736 Featured | CCT241736 is a novel, orally bioavailable Dual FLT3-Aurora Kinase Inhibitor. |
|
| DC8324 | CCT244747 Featured | CCT244747 represents the first structural disclosure of a highly selective, orally active CHK1 inhibitor and warrants further evaluation alone or combined with genotoxic anticancer therapies. |
|
| DC10498 | CCT251236 Featured | CCT251236 is an orally available pirin ligand from a heat shock transcription factor 1 (hsf1) phenotypic screen with an IC50 of 19 nM for inhibition of HSF1-mediated HSP72 induction. |
|
| DC9968 | CCT251545 Featured | CCT251545 is an orally bioavailable and potent inhibitor of WNT signaling with IC50 value of 5 nM. |
|
| DC9969 | CCT251921 | CCT251921 is a potent, selective, and orally bioavailable small-molecule modulators of the mediator complex-associated kinases CDK8 and CDK19. (IC50 data: CDK8:=2.3 nM; CDK19 = 2.6 nM). |
|
| DC10206 | CCX140 | CCX140 is a potent CCR2 antagonist. |
|
| DC12549 | CCX-354 | CCX-354 (GSK-2941266, CCX354-C, CCX354) is a potent, selective, orally-available CCR1 antagonist for the treatment of inflammatory diseases such as rheumatoid arthritis (RA).. |
|
| DC10955 | CD12681 | CD12681 (CD-12681) is a potent, selective RORγ inverse agonist with IC50 of 19 nM, displays no activity against a panel of nuclear receptors (RORα, RARγ, LXRβ, PPARγ and VDR). |
|
| DC20332 | CD38 inhibitor 78c Featured | CD38 inhibitor 78c is a potent, specific, reversible CD38 inhibitor with Ki of 14.5 nM for recombinant human CD38. |
|
| DC10491 | CD437 Featured | CD437 is a synthetic retinoid that is an RARγ-selective agonist. It displays RARγ-dependent and -independent effects on differentiation and apoptosis. |
|
| DC20877 | S8 | Cdc25 inhibitor S8 is an anti-fungal small molecule that inhibits cdc25 phosphatase with Ki of 140 uM. |
|
| DC10909 | BN82002 Featured | CDC25 Phosphatase Inhibitor I, BN82002, is a cell-permeable ortho-hydroxybenzylamino compound that has been reported to display antitumor properties. |
|
| DC21877 | Cdc7 inhibitor | Cdc7 inhibitor is a potent inhibitor of Cdc7 kinase with pIC50 of 10.01 against CDC7/DBF4 in TR-FRET assays.. |
|
| DC10433 | CDD3505 | CDD3505 is used for elevating high density lipoprotein cholesterol (HDL) by inducing hepatic cytochrome P450IIIA (CYP3A) activity. |
|
| DC10432 | CDD3506 | CDD3506 is used for elevating high density lipoprotein cholesterol (HDL) by inducing hepatic cytochrome P450IIIA (CYP3A) activity. |
|
| DC22051 | CDD-450 | CDD-450 is an unique inhibitor that selectively blocks p38α activation of proinflammatory kinase MAPK-MK2 while sparing p38α activation of PRAK and ATF2. |
|
| DC8361 | CDDO(Bardoxolone; RTA 401) Featured | CDDO is a synthetic oleanane triterpenoid that blocks the cellular synthesis of inducible nitric oxide synthase and inducible COX-2 in INF-γ-activated mouse macrophages with an IC50 value of 0.4 nM. |
|
| DC12026 | CDDO-2P-Imidazolide Featured | CDDO-2P-Im is a new analogue of CDDO-Imidazolid,showing better bioactive than CDDO-Imidazolid. |
|
| DC12027 | CDDO-3P-Imidazolide Featured | CDDO-3P-Im is a new analogue of CDDO-Imidazolid,showing better bioactive than CDDO-Imidazolid. |
|
| DC12025 | CDDO imidazolide Featured | CDDO-imidazolide is a potent inducer of heme oxygenase-1 and Nrf2/ARE signaling,with potent antiproliferative, differentiating, and anti-inflammatory activities. |
|
| DC9277 | C-DIM12 Featured | C-DIM12 is a novel synthetic activator of Nurr1. |
|
| DC10792 | DIM-C-pPhOCH3(C-DIM5) Featured | C-DIM5 is a Nur77 agonist. Activation of the orphan nuclear receptor Nur77 by C-DIM5 is associated with decreased cancer cell survival, |
|
| DC11158 | CDK12 inhibitor 2 | CDK12 inhibitor 2 is a potent, selective, non-covalent CDK12 inhibitor with IC50 of 52 nM, displays >192-fold selectivity over CDK2/7/8/9. |
|
| DC11872 | CDK12 inhibitor E9 S-isomer | CDK12 inhibitor E9 S-isomer (E9, CDK12-IN-E9) is a clinical analog of THZ1 and a selective, covalent CDK12 inhibitor that is not susceptible to ABC transporter-mediated drug efflux. |
|
| DC20334 | CDK2 inhibitor 73 Featured | CDK2 inhibitor 73 is a potent, selective CDK2 inhibitor with IC50 of 44 nM for CDK2/cyclin A, displays 2,000-fold selectivity over CDK1/cyclin B (IC50=86 uM).. |
|
| DC8596 | Cdk4/6 Inhibitor IV | Cdk4/6 Inhibitor IV is a cell-permeable triaminopyrimidine compound acting as a reversible and ATP-competitive inhibitor of Cdk4/6 (IC50 = 1.5 µM and 5.6 µM for Cdk4/D1 and Cdk6/D1, respectively) |
|
